- Home
- SABA vs ABOS Comparison
SABA vs ABOS Comparison
Compare SABA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.48
Company Overview
Basic Information| Metric | SABA | ABOS |
|---|---|---|
| Founded | 1988 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.3M | 197.9M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SABA | ABOS |
|---|---|---|
| Price | $8.31 | $2.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 32.5K | ★ 329.0K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 12.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.96 | $1.21 |
| 52 Week High | $9.38 | $3.60 |
Technical Indicators
Market Signals| Indicator | SABA | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 49.21 | 58.55 |
| Support Level | $8.19 | $2.13 |
| Resistance Level | $8.41 | $2.77 |
| Average True Range (ATR) | 0.12 | 0.12 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 50.30 | 96.20 |
Price Performance
Historical Comparison SABA
ABOS
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.